Download PDF
Thromb Haemost 1992; 68(01): 064-068
DOI: 10.1055/s-0038-1656319
Original Article
Schattauer GmbH Stuttgart

The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model

Petr Klement
The Dept. of Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada, the Biogen Inc., Cambridge, MA, USA, and the Department of Pathology, University of Toronto, Toronto, Ontario, Canada
,
Anita Borm
The Dept. of Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada, the Biogen Inc., Cambridge, MA, USA, and the Department of Pathology, University of Toronto, Toronto, Ontario, Canada
,
Jack Hirsh
The Dept. of Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada, the Biogen Inc., Cambridge, MA, USA, and the Department of Pathology, University of Toronto, Toronto, Ontario, Canada
,
John Maraganore
The Dept. of Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada, the Biogen Inc., Cambridge, MA, USA, and the Department of Pathology, University of Toronto, Toronto, Ontario, Canada
,
Gregory Wilson
The Dept. of Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada, the Biogen Inc., Cambridge, MA, USA, and the Department of Pathology, University of Toronto, Toronto, Ontario, Canada
,
Jeffrey Weitz
The Dept. of Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada, the Biogen Inc., Cambridge, MA, USA, and the Department of Pathology, University of Toronto, Toronto, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 06 November 1991

Accepted after revision 06 February 1992

Publication Date:
03 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Successful coronary thrombolysis depends on rapidly restoring blood flow and maintaining patency of the infarct-related artery. Although widely used as an adjunct to lytic therapy, heparin is limited in its ability to produce these effects. Since the limitations of heparin may reflect its inability to inactivate clot-bound thrombin, we developed a rat model of tissue plasminogen activator (t-PA) induced thrombolysis to compare doses of heparin, hirudin, hirulog (a synthetic hirudin-derived peptide), and D-Phe-Pro-ArgCH2Cl (PPACK) that produced a 4-fold prolongation of the baseline activated partial thromboplastin time (APTT) with saline in terms of their ability to accelerate thrombolysis and to prevent reocclusion. A thrombus rich in red cells and fibrin was formed in the distal aorta by applying an external constrictor after denuding the endothelium with a balloon catheter. Thrombolysis was induced with t-PA (1 mg/kg bolus, followed by 1 mg kg–1 h–1 over 30 min) and the rats were then randomized to receive a concomitant 80 min infusion of a thrombin inhibitor or saline. By continuously monitoring blood flow and pre- and post-stenotic blood pressures, the time to clot lysis, and the number of reocclusions were determined. Compared to saline, heparin had no significant effect on these variables. In contrast, hirudin, hirulog, and PPACK significantly (p <0.01) increased the percentage of the time that the vessel remained patent from 63.9 ± 7.7 to 90.7 ± 2.2, 94.0 ± 0.9, and 94.7 ± 1.0%, respectively by significantly (p <0.01) decreasing the number of reocclusions. The superiority of the antithrombin III-independent inhibitors over heparin supports the hypothesis that the limited effectiveness of heparin in this setting reflects its inability to inactivate clot-bound thrombin. Compared to saline, hirulog and PPACK also significantly (p <0.02) accelerated the time to thrombolysis from 10.5 ± 2.3 to 4.4 ± 0.6, and 4.2 ± 0.8 min, respectively, whereas heparin and hirudin did not. The ability of the lower molecular weight inhibitors of thrombin to accelerate lysis may reflect their greater accessibility to clot-bound thrombin. These findings raise the possibility that the antithrombin III-independent inhibitors of thrombin may not be equally effective as adjuncts to thrombolytic therapy with t-PA.

 

  • References

  • 1 Popma JJ, Topol EJ. Adjuncts to thrombolysis for myocardial reperfusion. Ann Intern Med 1991; 115: 34-44
    CrossrefPubMedSearch in Google Scholar
  • 2 Hsai J, Hamilton WP, Leiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437
    CrossrefPubMedSearch in Google Scholar
  • 3 Bleich SD, Richard R, Teichman S. Effect of heparin on coronary artery patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417
    CrossrefPubMedSearch in Google Scholar
  • 4 Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. and the TAMI Study Group A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-286
    CrossrefPubMedSearch in Google Scholar
  • 5 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623
    CrossrefPubMedSearch in Google Scholar
  • 6 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedSearch in Google Scholar
  • 7 Mirshani M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 1989; 74: 1025-1030
    PubMedSearch in Google Scholar
  • 8 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096-104
    PubMedSearch in Google Scholar
  • 9 Rydel TJ, Ravicandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton II JW. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990; 249: 277-280
    CrossrefPubMedSearch in Google Scholar
  • 10 Maraganore J, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8698
    PubMedSearch in Google Scholar
  • 11 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton II JW. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101
    CrossrefPubMedSearch in Google Scholar
  • 12 Skrzypczak-Jankus E, Carperos V, Bourdon P, Fenton II JW, Maraganore JM, Tulinsky A. X-ray crystallographic structures of the hirugen: thrombin and hirulog: thrombin complexes at 2.2 A resolution. Thromb Haemostas 65: 507 (abstract)
    PubMed
  • 13 Kettner C, Shaw E. D-Phe-Pro-ArgCH2CL. A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
    PubMedSearch in Google Scholar
  • 14 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-10425
    PubMedSearch in Google Scholar
  • 15 Berliner LJ, Sugawara Y, Fenton II JW. Human α-thrombin binding to nonpolymerized fibrin-sepharose: Evidence for an anionic binding region. Biochemistry 1985; 24: 7005-7009
    CrossrefPubMedSearch in Google Scholar
  • 16 Kaminski M, McDonagh J. Inhibited thrombins: Interactions with fibrinogen and fibrin. Biochem J 1987; 242: 881-887
    CrossrefPubMedSearch in Google Scholar
  • 17 Yasuda T, Gold HK, Fallon J, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Colleen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284-1291
    CrossrefPubMedSearch in Google Scholar
  • 18 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-677
    CrossrefPubMedSearch in Google Scholar
  • 19 Shebuski R, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 1990; 82: 169-177
    CrossrefPubMedSearch in Google Scholar
  • 20 Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. Thromb Res 1984; 34: 431-437
    CrossrefPubMedSearch in Google Scholar
  • 21 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induced transient thrombin activity. Blood 1988; 72: 616-620
    PubMedSearch in Google Scholar
  • 22 Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990; i: 481-482
    PubMedSearch in Google Scholar
  • 23 Weitz JI, Leslie B, Hudoba M. Thrombin remains bound to soluble fibrin degradation products and is partially protected from inhibition by heparin-antithrombin III. Thromb Haemostas 1991; 65: 931 (abstract)
    PubMedSearch in Google Scholar
  • 24 Eisenberg PR, Miletich JP, Sobel BE, Jaffe AS. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA). Thromb Res 1988; 50: 707-717
    CrossrefPubMedSearch in Google Scholar
  • 25 Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73: 185-190
    PubMedSearch in Google Scholar